SCHEMBL27458692

SCHEMBL27458692

Cc1ncc2c(n1)N(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
ESR2 Q92731 1/20 0.38
NR1H2 P55055 1/20 0.37
CYP11B2 P19099 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
PIK3CD O00329 2/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
DHODH Q02127 1/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CA P42336 1/20 0.35
USP1 O94782 1/20 0.35
GPR119 Q8TDV5 2/20 0.34
GRM5 P41594 1/20 0.34
CHRM4 P08173 1/20 0.34
DRD2 P14416 1/20 0.34
HTR7 P34969 1/20 0.34
DDB1 Q16531 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27458686 0.85 NR1H2 (0.41) MAPTESR2NR1H2CYP11B2PIK3CD
SCHEMBL27458695 0.85 MAPT (0.42) MAPTESR2NR1H2CYP11B2CKS1B
SCHEMBL30954006 0.85 NR1H2 (0.41) MAPTESR2NR1H2CYP11B2PIK3CD
SCHEMBL14380649 0.80 ESR2 (0.44) MAPTESR2NR1H2GPR119GRM5
SCHEMBL30513283 0.80 CYP11B2 (0.41) MAPTESR2NR1H2CYP11B2GPR119
SCHEMBL10053887 0.78 CYP11B2 (0.45) MAPTESR2NR1H2CYP11B2CHRM4
SCHEMBL31073472 0.76 MAPT (0.55) MAPTESR2NR1H2CCNA2CDK2
SCHEMBL27097490 0.76 CHRM4 (0.43) MAPTESR2NR1H2DHODHGPR119
SCHEMBL2964825 0.75 CYP11B2 (0.42) ESR2NR1H2CYP11B2CHRM4DRD2
SCHEMBL30462275 0.74 POLB (0.47) MAPTESR2NR1H2CYP11B2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137984-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed